Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts

CONCLUSION: In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.PMID:35763708 | DOI:10.1200/JCO.21.02698

Source: Clinical Lymphoma and Myeloma - June 28, 2022 Category: Cancer & Oncology Authors: Peter Martin Jonathon B Cohen Michael Wang Anita Kumar Brian Hill Diego Villa Jeffrey M Switchenko Brad Kahl Kami Maddocks Natalie S Grover Keqin Qi Lori Parisi Katherine Daly Angeline Zhu Gilles Salles Source Type: research